According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
A number of other research analysts also recently weighed in on the stock. Craig Hallum reduced their target price on shares of Sientra from $20.00 to $14.00 and set a buy rating for the company in a research report on Thursday, July 25th. Maxim Group reissued a buy rating and set a $12.00 target price (down from $16.00) on shares of Sientra in a research report on Friday, August 9th. ValuEngine raised shares of Sientra from a sell rating to a hold rating in a research report on Thursday, August 1st. Wells Fargo & Co raised shares of Sientra from a market perform rating to an outperform rating and increased their target price for the company from $8.00 to $10.00 in a research report on Wednesday, June 5th. Finally, BidaskClub raised shares of Sientra from a strong sell rating to a sell rating in a research report on Thursday, April 25th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $15.75.
Sientra (NASDAQ:SIEN) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported ($1.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.50). Sientra had a negative net margin of 151.96% and a negative return on equity of 123.80%. The company had revenue of $20.53 million for the quarter, compared to the consensus estimate of $19.04 million. During the same period in the prior year, the company earned ($0.73) earnings per share. The firm’s revenue was up 17.0% on a year-over-year basis. Equities analysts expect that Sientra will post -2.4 EPS for the current fiscal year.
In other Sientra news, Director Keith J. Sullivan acquired 20,869 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The stock was bought at an average cost of $5.75 per share, with a total value of $119,996.75. Following the acquisition, the director now owns 203,141 shares in the company, valued at $1,168,060.75. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Paul Sean Little acquired 17,391 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The stock was acquired at an average cost of $5.75 per share, with a total value of $99,998.25. Following the completion of the acquisition, the chief financial officer now owns 94,891 shares in the company, valued at approximately $545,623.25. The disclosure for this purchase can be found here. 13.30% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SIEN. Point72 Hong Kong Ltd lifted its stake in Sientra by 282.5% in the 2nd quarter. Point72 Hong Kong Ltd now owns 3,997 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 2,952 shares in the last quarter. BNP Paribas Arbitrage SA lifted its stake in Sientra by 97,300.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,870 shares of the medical instruments supplier’s stock worth $42,000 after purchasing an additional 4,865 shares in the last quarter. NumerixS Investment Technologies Inc purchased a new stake in Sientra in the 2nd quarter worth approximately $59,000. Private Advisor Group LLC purchased a new stake in Sientra in the 2nd quarter worth approximately $62,000. Finally, Metropolitan Life Insurance Co. NY lifted its stake in Sientra by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,191 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 6,397 shares in the last quarter. 86.93% of the stock is owned by institutional investors.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Read More: Convertible Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.